

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

Product Datasheet

Recombinant 2019-nCoV S1 Protein EBT-EPT025

Article Name	Recombinant 2019-nCoV S1 Protein
Biozol Catalog Number	EBT-EPT025
Supplier Catalog Number	EPT025
Alternative Catalog Number	EBT-EPT025-50
Manufacturer	ELK Biotechnology
Category	Proteine/Peptide
Product Description	Recombinant SARS-CoV-2 S1 Protein is produced by our Mammalian expression system and the target gene encoding Gln14-Arg685 is expressed....
Molecular Weight	Molecular weight: 78.3kDa. Apparent molecular weight: 100-130kDa, reducing conditions
UniProt	QHD43416.1
Purity	Greater than 95% as determined by reducing SDS-PAGE.

Application Notes

Biological activity: Immobilized 2019-nCoV S1 Protein(CatDRA35) at 2µg/ml (100 µl/well) can bind Human ACE-2-Fc(CatC05Y). The ED50 of Human ACE-2-Fc(CatC05Y) is 15-150 ng/ml. Background: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. Its been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity